AstraZeneca Under Scrutiny Again as Countries Spend Billions Purchasing Its Low-Cost Vaccine

Read more on this subject: Vaccines and Vaccinations
News Story Source: Childrens Health Defense
AstraZeneca's COVID vaccine faced new controversy this week after a trial participant in India alleged that the vaccine caused him serious "neurological and psychological" symptoms.

The accusation was the latest in a series of complaints or concerns surrounding Covishield, the AstraZeneca vaccine being developed in partnership with Oxford University.

Yet despite concerns about safety and trial design, countries are already spending billions of dollars in taxpayer funds to purchase AstraZeneca's vaccine, in part because, compared with frontrunners Moderna and Pfizer, AstraZeneca's vaccine is easier to store and faster to distribute.

Read More or Make a Comment

Bookmark the permalink.

Comments are closed.